Telomir Pharmaceuticals, Inc. has announced a strategic partnership with Linical, a global contract research organization (CRO), to support its FDA-cleared Phase 1/2 clinical trial for Telomir-Zn. This trial aims to evaluate the treatment's efficacy in patients with advanced or metastatic triple-negative breast cancer (TNBC). The collaboration is a crucial step for Telomir as it prepares to initiate clinical trials in the first quarter of 2027.

Telomir Pharmaceuticals, Inc., based in Miami, Florida, is a clinical-stage biotechnology company focused on developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Telomir is listed on the Nasdaq under the ticker symbol TELO.

According to the recent SEC filing, Telomir has executed a Master Services Agreement and clinical trial Work Order with Linical, establishing the operational framework necessary to advance the study. The engagement follows the clearance of Telomir's Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), marking a significant operational milestone.

“Following FDA clearance of our IND, our priority has been to establish the clinical infrastructure necessary to advance Telomir-Zn into patients,” said Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals. “We selected Linical for its extensive oncology experience, including breast cancer and early-phase clinical development.”

Linical brings over two decades of experience in oncology clinical development, with a significant portion of its work focused on early-phase studies. The CRO's capabilities encompass various aspects of clinical trials, including startup, investigator-site coordination, patient recruitment, clinical monitoring, project management, biometrics, and regulatory support.

The partnership is expected to enhance Telomir's preparations for the clinical evaluation of Telomir-Zn, which is designed to regulate intracellular metal homeostasis and potentially reactivate silenced tumor suppressor genes involved in controlling cancer growth. Preclinical research has shown promise, demonstrating antitumor activity in TNBC models.

Telomir-Zn will be evaluated for its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity as a monotherapy in patients with advanced or metastatic TNBC. The company is targeting clinical trial initiation in early 2027.

This development not only marks a pivotal moment for Telomir Pharmaceuticals but also highlights the ongoing trend in the pharmaceutical industry towards collaborations with specialized CROs. Such partnerships are increasingly seen as essential for enhancing clinical trial efficiency and effectiveness, particularly in the competitive landscape of pharmaceutical preparations.

As Telomir moves forward with its clinical plans, it will be interesting to see how this partnership influences its position in the market and whether it will lead to advancements in treatment options for patients battling triple-negative breast cancer.